Bolivar R, Weaver S S, Bodey G P
Antimicrob Agents Chemother. 1982 Apr;21(4):641-5. doi: 10.1128/AAC.21.4.641.
The activity of temocillin (BRL 17421), a new penicillin, was tested in vitro against 653 isolates of gram-negative bacilli and gram-positive cocci. The drug was compared with other beta-lactam antibiotics and tobramycin. It inhibited the majority of gram-negative bacilli tested except for Pseudomonas aeruginosa and Acinetobacter calcoaceticus, which were highly resistant. It was active against more than 50% of the multiresistant strains tested. Temocillin was more active than mezlocillin against most gram-negative bacilli and more active than moxalactam, ceftriaxone, and ceftazidime against Enterobacter spp. In general, it was slightly less active than the other drugs tested and had no activity against the gram-positive cocci. There was no significant change in drug activity when pH and medium were varied, and the effect of serum binding was minimal. There was no significant inoculum effect when the size of the inoculum was increased from 10(4) to 10(6) organisms per ml.
新型青霉素替莫西林(BRL 17421)的活性在体外针对653株革兰氏阴性杆菌和革兰氏阳性球菌进行了测试。该药物与其他β-内酰胺类抗生素及妥布霉素进行了比较。它抑制了除铜绿假单胞菌和乙酸钙不动杆菌(这两种菌具有高度耐药性)之外的大多数测试革兰氏阴性杆菌。它对超过50%的测试多重耐药菌株有活性。替莫西林对大多数革兰氏阴性杆菌的活性比美洛西林更强,对肠杆菌属细菌的活性比拉氧头孢、头孢曲松和头孢他啶更强。总体而言,它的活性略低于所测试的其他药物,且对革兰氏阳性球菌无活性。当pH值和培养基改变时,药物活性无显著变化,血清结合的影响极小。当接种量从每毫升10⁴个菌增加到10⁶个菌时,无显著的接种量效应。